A successful immunisation program that yields robust immunity with the lowest possible performance consequences requires the formulation of a consistent vaccine based on viable sporulated oocyst counts. These counts can accurately be made by means of an assay that detects the proportion of non-viable sporocysts in the original oocyst population.